Синдром поликистозных яичников как фактор риска сосудистых, метаболических и гинекологических заболеваний

Обложка

Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Обзор литературы, в котором рассматривается роль различных факторов патогенеза синдрома поликистозных яичников в возникновении у женщин с данной патологией сосудистых, метаболических и гинекологических заболеваний. Обсуждается роль инсулинорезистентности и возможные механизмы ее влияния на общее и репродуктивное здоровье женщины.

Об авторах

Н. А. Беляков

Медицинская академия последипломного образования

Автор, ответственный за переписку.
Email: shabanov@mail.rcom.ru

Член-корреспондент РАМН

Россия, 193015, Санкт-Петербург, ул. Кирочная, 41

С. Ю. Чубриева

Медицинская академия последипломного образования

Email: shabanov@mail.rcom.ru
Россия, 193015, Санкт-Петербург, ул. Кирочная, 41

Н. В. Глухов

Медицинская академия последипломного образования

Email: shabanov@mail.rcom.ru
Россия, 193015, Санкт-Петербург, ул. Кирочная, 41

Список литературы

  1. Анциферов М. Б., Григорян О. Р., Чернова Т. О. Возможности применения препарата Сиофор (метформина гидрохлорида) у женщин с синдромом поликистозных яичников и избыточной массой тела // Пробл. репрод. 2001. Т. 7. № 2. С. 49-55.
  2. Беляков Н. А., Чубриева С. Ю., Глухов Н. В. Инсулинорезистентность и синдром поликистозных яичников. Часть I. Исторические данные, распространенность, терминология и классификация, клеточные и молекулярные механизмы, клинические признаки и диагностические критерии // Эфферентная терапия. 2002. Т. 8. № 2. С. 3-11.
  3. Беляков Н. А., Чубриева С. Ю., Глухов Н. В. Инсулинорезистентность и синдром поликистозных яичников. Часть II. Патогенез, роль гиперинсулинемии и гиперандрогенемии, генетическая взаимосвязь // Эфферентная терапия. 2002. Т. 8. № 3. С. 16-29.
  4. Геворкян М. А., Манухин И. Б., Кушлинский Н. Е., Кухаркина О. Б. Метаболические нарушения у больных с синдромом поликистозных яичников // Пробл. репрод. 2000. Т. 6. № 6. С. 38-42.
  5. Назаренко Г А., Дуринян Э. Р, Чечурова Т. Н. Здоровье женщин с нарушениями овуляции // Пробл. репрод. 1999. Т. 5. № 2. С. 48-51.
  6. Овсянникова Т. В., Демидова И. Ю., Фанченко Н. Д. и др. Метаболические нарушения у пациенток с хронической ановуляцией и гиперандрогенией // Пробл. репрод. 1999. Т. 5. № 2. С. 34-37.
  7. Amowitz L. L., Sobel В. Е. Polycystic ovary syndrome. Cardiovascular consequences of polycystic ovary syndrome // Endocrinol. Metab. Clin. North. Am. 1999. Vol. 28. № 2. P. 439-158.
  8. Andersen P., Seljeflot I., Abdelnoor M. et al. Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome // Metabolism. 1995. Vol. 44. P. 611-616.
  9. Anderson К. E., Sellers T. A., Chen P-L. et al. Association of Stein-Leventhal syndrome with the incidence of postmenopausal breast carcinoma in a large prospective study of women in Iowa // Cancer. 1997. Vol. 79. P. 494-499.
  10. Arslanian S. A., Lewy V. D., Danadian K. Glucose intolerance in obese adolescents with polycystic ovary syndrome: roles of insulin resistance and в-cell dysfunction and risk of cardiovascular disease // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 1. P. 66-71.
  11. Atiomo W. U., Condon J., Adekanmi O. et al. Are women with polycystic ovary syndrome resistant to activated protein C? // Fertil. Steril. 2000. Vol. 74. № 6. P. 1229-1232.
  12. Atiomo W.U., Fox R., Condon J. E. et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS) // Clin. Endocrinol. (Oxf.). 2000. Vol. 52. № 4. P. 487-492.
  13. Balletshofer В. M., Rittig K., Volk A. et al. Impaired non-esterified fatty acid suppression is associated with endothelial dysfunction in insulin resistant subjects // Horm. Metab. Res. 2001. Vol. 33. P. 428-431.
  14. Barrett-Conner E., Goodman-Gruen D. Dehydroepiandrosterone sulfate does not predict cardiovascular disease in post-menopausal women // Circulation. 1995. Vol. 91. P. 1757.
  15. Battilana P., Seematter G., Schneiter Ph. et al. Effects of free fatty acids on insulin sensitivity and hemodynamics during mental stress // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 1. P. 124-128.
  16. Birdsall M. A., Farquhar С. M., White H. D. Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization // Ann. Intern. Med. 1997. Vol. 126. P. 32-35.
  17. Brussaard H. E., Gevers-Leuven J. A., Frolich M. et al. Short-term oestrogen replacement therapy improves insulin resistance, lipids and fibrinolysis in postmenopausal women with NIDDM // Diabetologia. 1997. Vol. 40. P. 843—849.
  18. Burghen G. A., Givens J. R., Kitabchi A. E. Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease // J. Clin. Endocrinol. Metab. 1980. Vol. 50. P. 113-116.
  19. Chamlian D. L., Taylor H. B. Endometrial hyperplasia in young women // Obstet. Gynecol. 1970. Vol. 36. P. 659-665.
  20. Christian R. C., Behrenbeck T., Fitzpatrick L. A. Clinical hyperandrogenism and body mass index predict coronary calcification in premenopausal women with polycystic ovary syndrome (PCOS) // Endocr. Soc. Abs. 2000. P. 400.
  21. Cibula D., Cifkova R., Fanta M. et al. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome // Hum. Reprod. 2000. Vol. 15. № 4. P. 785-789.
  22. Clifford K., Rai R., Watson H. et al. Does suppressing luteinizing hormone secretion reduce the miscarriage rate? Results of a randomized controlled trial // BMJ. 1996. Vol. 312. P. 1508-1511.
  23. Colilla S., Cox N. J., Ehrmann D. A. Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their firstdegree relatives // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 5. P. 2027-2031.
  24. Conn J. J., Jacobs H. S., Conway G. S. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus // Clin. Endocrinol. 2000. Vol. 52. P. 81-86.
  25. Conway G. S., Agrawal R., Betteridge D. J., Jacobs H. S. Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome // Clin. Endocrinol. (Oxf. ). 1992. Vol. 37. P. 119-125.
  26. Coulam С. B., Annegers J. F., Kranz J. S. Chronic anovulation syndrome and associated neoplasia // Obstet. Gynecol. 1983. Vol. 61. P. 403-407.
  27. Dahlgren E., Friberg L.-G., Johansson S. et al. Endometrial carcinoma; ovarian dysfunction - a risk factor in young women // J. Obstet. Gynecol. Reprod. Biol. 1991. Vol. 41. P. 143-150.
  28. Dahlgren E., Janson P. O., Johansson S. et al. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women // Acta Obstet. Gynecol. Scand. 1992. Vol. 71. № 8. P. 599-604.
  29. Dahlgren E., Janson P. O., Johansson S. et al. Hemostatic and metabolic variables in women with polycystic ovary syndrome // Fertil. Steril. 1994. Vol. 61. P. 45 5-460.
  30. Dahlgren E., Johansson S., Lindstedt G. et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up focusing on natural history and circulating hormones // Fertil. Steril. 1992. Vol. 57. P. 505-513.
  31. Dejager S., Pichard C., Giral P. et al. Smaller LDL particle size in wcmen with polycystic ovary syndrome compared to controls // Clin. Endocrinol. (Oxf. ). 2001. Vol. 54. № 4. P. 455-462.
  32. Den Tonkelaar I., de Waard F. Regularity and length of menstrual cycles in women aged 41-46 in relation to breast cancer risk: Results from the DOM-project // Breast Cancer Research and Treatment. 1996. Vol. 38. P. 253-258.
  33. de Vries M. J., Dekker G. A., Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study // Eur. J. Obstet. Gynecol. Reprod. Biol. 1998. Vol. 76. № l.P. 91-95.
  34. Diamanti-Kandarakis E., Spina G., Kouli C., Migdalis I. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 10. P. 4666-4673.
  35. Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus // Am. J. Med. 1995. Vol. 98. P. 33S-39S.
  36. Dunaif A., Graf M., Mandeli J. et al. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance and/or hyperinsulinemia // J. Clin. Endocrinol. Metab. 1987. Vol. 65. P. 499-507.
  37. Ehrmann D. A., Barnes R. B., Rosenfield R. L. et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome // Diabetes Care. 1999. Vol. 22. P. 141-146.
  38. Ehrmann D. E., Schneider D. J., Sobel В. E. et al. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 1997. Vol. 82. P. 2108-2116.
  39. Elting M. W., Korsen T. J. M., Bezemer P D., Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a followup study of a Dutch PCOS population // Hum. Reprod. 2001. Vol. 16. № 3. P. 556-560.
  40. Elting M. W., Korsen T. J. M., Rekers-Mombarg L. T. M., Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing // Hum. Reprod. 2000. Vol. 15. № l.P. 24-28.
  41. Elting M. W., Korsen T. J. M., Schoemaker J. Obesity, rather than menstrual cycle pattern or follicle cohort size, determines hyperinsuli- naemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome // Clin. Endocrinol. (Oxf). 2001. Vol. 55. № 6. P. 767-776.
  42. Festa A., D’Agostino R. J., Howard G. et al. Chronic subclinical inflammation as a part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS) // Circulation. 2000. Vol. 102. P. 42-47.
  43. Fogel R. B., Malhotra A., Pillar G. et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 3. P. 1175-1180.
  44. Fridstrom M., Nisell H., Sjoblom P. et al. Are women with polycystic ovary syndrome at an increased risk of pregnancy-induced hypertension and/or preeclampsia? // Hypertens. Preg. 1999. Vol. 18. P. 73-80.
  45. Futterweit W. Pathophysiology of polycystic ovarian disease // Polycystic Ovarian Disease / New York, Springer-Verlag, 1984.
  46. Gammon M.D., Thompson W. D. Infertility and breast cancer: A population-based case control study // Am. J. Epidemiol. 1990. Vol. 132. P. 708-716.
  47. Gjonnaess H. The course and outcome of pregnancy after electrocautery in women with polycystic ovarian syndrome: the influence of body weight // Br. J. Obstet. Gynaecol. 1989. Vol. 96. P. 714-719.
  48. Glueck C. J., Wang R., Fontaine R. N. et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome // Metabolism. 1999. Vol. 48. № 12. P. 1589-1595.
  49. Guzick D. S., Talbott E. O., Sutton-Tyrrell K. et al. Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study // Am. J. Obstet. Gynecol. 1996. Vol. 174. P. 1224-1232.
  50. Helzlsouer K. J., AlbergA. J., Gordon G. B. et al. Serum gonadotropins and steroid hormones and the development of ovarian cancer // JAMA. 1995. Vol. 274. P. 1926-1930.
  51. Hollenbeck C., Reaven G. M. Variations in insulin-stimulated glucose uptake in healthy individuals with normal glucose tolerance // J. Clin. Endocrinol. Metab. 1987. Vol. 64. P. 1169-1173.
  52. Holte J., Bergh T., Berne C., Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables // Clin. Endocrinol. (Oxf). 1994. Vol. 41. P. 463-471.
  53. Holte J., Gennarelli G., Berne C. et al. Elevated ambulatory day-time blood pressure in women with polycystic ovary syndrome: a sign of a prehypertensive state? // Hum. Reprod. 1996. Vol. 11. P. 23-28.
  54. Holte J., Gennarelli G., Wide L. et al. High prevalence of polycystic ovaries and associated clinical, endocrine, and metabolic features in women with previous gestational diabetes mellitus // J. Clin. Endocrinol. Metab. 1998. Vol. 83. № 4. P. 1143-1150.
  55. Homburg R., Armar N. A., Eshel A. et al. Influence of serum luteinizing hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome // BMJ. 1988. Vol. 297. P. 1024-1026.
  56. Hu F. B., Willett W. C., Manson J. E. et al. Snoring and risk of cardiovascular disease in women //J. Am. Coll. Cardiol. 2000. Vol. 35. P. 308-313.
  57. Ibanez L., Aulesa C., Potau N. et al. Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome? // Pediatr. Res. 2002. Vol. 51. № 2. P. 244-248.
  58. Jakubowicz D. J., Seppa I a M., Jakubowicz S. et al. Insulin reduction with metformin increases luteal phase serum glycodelin insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 3. P. 1126-1133.
  59. Kelly C. J. G., Lyall H., Petrie J. R. et al. Lowgrade chronic inflammation in women with polycystic ovarian syndrome // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 6. P. 2453-2455.
  60. Kelly C. J. G., Lyall H., Petrie J. R. et al. A specific elevation in tissue plasminogen activator antigen in women with polycystic ovarian syndrome // J. Clin. Endocrinol. Metab. 2002. Vol. 87. № 7. P. 3287-3290.
  61. Kelly C. J. G., Speirs A., Gould G. W. et al. Altered vascular function in young women with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 2002. Vol. 87. № 2. P. 742-746.
  62. Kern W., Fittje A., Fohr W. et al. Increase in systolic blood pressure and catecholamine level during hyperinsulinemia in a placebo-controlled euglycemic clamp in healthy subjects // Exp. Clin. Endocrinol. Diabetes. 2000. Vol. 108. P. 498-505.
  63. Knochenhauer E. S., Key T. J., Kahsar-Miller M. et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the Southeastern United States: a prospective study //J. Clin. Endocrinol. Metab. 1998. Vol. 83. № 9. P. 3078-3082.
  64. Koivunen R. M., Juutinen J., Vauhkonen L. et al. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 6. P. 2591-2599.
  65. Kousta E., Cela E., Lawrence N. J. et al. The prevalence of polycystic ovaries in women with a history of gestational diabetes // Clin. Endocrinol. 2001. Vol. 53. P. 501-507.
  66. Laivuori H., Tikkanen M. J., Ylikorkala O. Hyperinsulinemia 17 years after pre-eclamptic first pregnancy // J. Clin. Endocrinol. Metab. 1996. Vol. 81. P. 2908-2911.
  67. Lakhani K., Constantinovici N., Purcell W. M. et al. Internal carotid artery haemodynamics in women with polycystic ovaries // Clin. Sci. 2000. Vol. 98. P. 661-665.
  68. Legro R. S., Blanche R., Krauss R. M., Lobo R. A. Alterations in atherogenic lipoproteins among hyperandrogenic women: influence of insulin and genetic factors // Program of the 40th Annual Meeting of the Society for Gynecologic Investigation. 1993. Abstract. P. 3 55-360.
  69. Legro R. S., Kunselman A. R., Dodson W., Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women // J. Clin. Endocrinol. Metab. 1999. Vol. 84. № 1. P. 165-169.
  70. Lemieux S., Lewis G. F., Ben-Chetrit A. et al. Correction of hyperandrogenemia by laparoscopic ovarian cautery in women with polycystic ovarian syndrome is not accompanied by improved insulin sensitivity or lipid-lipoprotein levels // J. Clin. Endocrinol. Metab. 1999. Vol. 84. № 11. P. 4278-4282.
  71. Lesser К. B., Garcia F. A. R. Association between polycystic ovary syndrome and glucose intolerance during pregnancy // J. Maternal Fetal Med. 1997. Vol. 6. P. 303-307.
  72. Levran D., Shoham Z., Habib D. et al. Glucose intolerance in pregnant women following treatment for sterility // Int. J. Fertil. 1990. Vol. 35. P. 157-159.
  73. Lieberman E. H., Gerhard M. D., Uehata A. et al. Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women // Ann. Intern. Med. 1994. Vol. 121. P. 936-941.
  74. Loucks T. L., Talbott E. O., McHugh К. R. et al. Do polycystic-appearing ovaries affect the risk of cardiovascular disease among women with polycystic ovary syndrome? // Fertil. Steril. 2000. Vol. 74. № 3. P. 547-5 52.
  75. Loverro G., Lorusso F., Mei L. et al. The plasma homocysteine levels are increased in polycystic ovary syndrome // Gynecol. Obstet. Invest. 2002. Vol. 53. № 3.P. 157-162.
  76. MacMahon B. Risk factors for endometrial cancer // Gynecol. Oncol. 1974. Vol. 2. P. 122-129.
  77. Macut D., Micic D., Cvijovic G. et al. Cardiovascular risk in adolescent and young adult obese females with polycystic ovary syndrome (PCOS) // J. Pediatr. Endocrinol. Metab. 2001. Vol. 14. P. 1353-1359.
  78. Mather K. J., Verma S, Corenblum B., Anderson T. J. Normal endothelial function despite insulin resistance in healthy women with the polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 2000. Vol. 85. № 5. P. 1851-1856.
  79. Mattson L. A., Cullberg G., Hamberger L. et al. Lipid metabolism in women with polycystic ovary syndrome: possible implications for an increased risk of coronary heart disease // Fertil. Steril. 1984. Vol. 42. P. 579-584.
  80. Meirow D., Schenker J. G. The link between female infertility and cancer: epidemiology and possible aetiologies // Hum. Reprod. Update. 1996. Vol. 2. P. 63-75.
  81. Mikola M., Hiilesmaa V., Halttunen M. et al. Obstetric outcome in women with polycystic ovarian syndrome // Hum. Reprod. 2001. Vol. 16. № 2. P. 226-229.
  82. Mooe T., Rabben T., Wiklund U. et al. Sleep-disordered breathing in women: occurrence and association with coronary artery disease // Am. J. Med. 1996. Vol. 101. P. 251-256.
  83. Naderali E. K., Brown M. J., Pickavance L. C. et al. Dietary obesity in the rat induces endothelial dysfunction without causing insulin resistance: a possible role for triacylglycerols // Clin. Sci. 2001. Vol. 101. P. 499-506.
  84. Niwa K., Imai A., Hashimoto M. et al. A casecontrol study of uterine endometrial cancer of pre- and post-menopausal women // Oncol. Reports. 2000. Vol. 7. P. 89-93.
  85. Norman R. J., Masters L., Milner C. R. et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or noninsulin dependent diabetes mellitus in polycystic ovarian syndrome // Hum. Reprod. 2001. Vol. 16. № 9. P. 1995-1998.
  86. Ovalle F., Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus // Fertil. Steril. 2002. Vol. 77. № 6. P. 1095-1105.
  87. Palmert M. R., Gordon С. M., Kartashov A. I. et al. Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 2002. Vol. 87. № 3. P. 1017-1023.
  88. Paradisi G., Fulghesu A. M., Ferrazzani S. et al. Endocrino-metabolic features in women with polycystic ovary syndrome during pregnancy // Hum. Reprod. 1998. Vol. 13. № 3. P. 542-546.
  89. Paradisi G., Steinberg H. O., Hempfling A. et al. Polycystic ovary syndrome is associated with endothelial dysfunction // Circulation. 2001. Vol. 103. P. 1410-1415.
  90. Peppard H. R., Iuorno M. J., Marfori J., Nestler J. E. Prevalence of polycystic ovary syndrome among premenopausal women with type 2 diabetes // Diabetes Care. 2001. Vol. 24. P. 1050-1052.
  91. Pierpoint T., McKeigue R M., Isaacs A. J. et al. Mortality of women with polycystic ovary syndrome at long-term follow-up // J. Clin. Epidemiol. 1998. Vol. 51. P. 5 81-5 86.
  92. Pirwany I. R., Fleming R., Greer L.A. et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and endocrine parameters // Clin. Endocrinol. (Oxf.). 2001. Vol. 54. P. 447-453.
  93. Potischman N., Hoover R. N., Brinton L. A. et al. Case-control study of endogenous steroid hormones and endometrial cancer // J. Natl. Cancer. Instit. 1996. Vol. 8 8. P. 1127-113 5.
  94. Prelevic G. M., Beljic T., Balint-Peric L., Ginsburg J. Cardiac flow velocity in women with the polycystic ovary syndrome // Clin. Endocrinol. (Oxf. ). 1995. Vol. 43. P. 677-681.
  95. Robinson S., Henderson A. D., Gelding S. V. et al. Dyslipidaemia is associated with insulin resistance in women with polycystic ovaries // Clin. Endocrinol. (Oxf). 1996. Vol. 44. № 3. P. 277-284.
  96. Robinson S., Kiddy D., Gelding S. V. et al. The relationship of insulin insensitivity to menstrual pattern in women with hyperandrogenism and polycystic ovaries // Clin. Endocrinol. (Oxf. ). 1993. Vol. 39. P. 351-355.
  97. Rosmond R., Chagnon Y. C., Holm G. et al. Hypertension in obesity and the leptin receptor gene locus // J. Clin. Endocrinol. Metab. 2000. Vol. 85. № 9. P. 3126-3131.
  98. Sagle M., Bishop K., Ridley N. et al. Recurrent early miscarriage and polycystic ovaries // BMJ. 1988. Vol. 297. P. 1027-1028.
  99. Sampson M., Kong C., Patel A. et al. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome // Clin. Endocrinol. (Oxf.). 1996. Vol. 45. P. 623-629.
  100. Schildkraut J. M., Schwingl P. J., Bastos E. et al. Epithelial ovarian cancer risk among women with polycystic ovary syndrome // Obstet. Gynecol. 1996. Vol. 88. P. 554-559.
  101. Seely E. W. Hypertension in pregnancy: a potential window into long-term cardiovascular risk in women // J. Clin. Endocrinol. Metab. 1999. Vol. 84. P. 1858-1861.
  102. Sobel В. E. Altered fibrinolysis and platelet function in the development of vascular complications of diabetes // Curr. Opin. Endocrinol. Diabetes. 1996. Vol. 3. P. 3 5 5-3 60.
  103. Solomon C. G., Carroll J. S., Okamura К. et al. Higher cholesterol and insulin levels are associated with increased risk for pregnancy-induced hypertension // Am. J. Hypertens. 1999. Vol. 12. P. 276-282.
  104. Solomon C. G., Hu F. B., Dunaif A. et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus // JAMA. 2001. Vol. 286. P. 2421-2426.
  105. Solomon C. G., Seely E. W. Hypertension in pregnancy. A manifestation of the insulin resistance syndrome? // Hypertension. 2001. Vol. 37. P. 232-239.
  106. Talbott E., Clerici A., Berga S. L. et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study // J. Clin. Epidemiol. 1998. Vol. 51. № 5. P. 415-422.
  107. Talbott E., Guzick D., Clerici A. et al. Coronary heart disease risk factors in women with polycystic ovary syndrome // Arterioscler. Thromb. Vasc. Biol. 1995. Vol. 15. P. 821-826.
  108. Talbott E., Guzick D., Sutton-Tyrrell К. et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women // Arterioscler. Thromb. Vasc. Biol. 2000. Vol. 20. P. 2414-2421.
  109. Tiras M. B., Yalcin R., Noyan V. et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome // Hum. Reprod. 1999. Vol. 14. № 8. P. 1949-1952.
  110. Toscano V., Bianchi P., Balducci R. et al. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism // Clin. Endocrinol. 1992. Vol. 3 6. P. 197-202.
  111. Tsanadis G., Vartholomatos G., Korkontzelos I. et al. Polycystic ovarian syndrome and thrombophilia // Hum. Reprod. 2002. Vol. 17. № 2. P. 314-319.
  112. Tulppala M., Stenman U., Cacciatore B., Ylikorkala O. Polycystic ovaries and levels of gonadotrophins and androgens in recurrent miscarriage: prospective study in 50 women // Br. J. Obstet. Gynaecol. 1993. Vol. 100. P. 348-3 52.
  113. Urman B., Sarac E., Dogan L., Gurgan T. Pregnancy in infertile PCOD patients: complications and outcome // J. Reprod. Med. 1997. Vol. 42. P. 501-505.
  114. Velazquez M. E., Bellabarba G. A., Mendoza S., Sanchez L. Postprandial triglyceride response in patients with polycystic ovary syndrome: relationship with waist-to-hip ratio and insulin // Fertil. Steril. 2000. Vol. 74. P. 1159-1163.
  115. Vgontzas A. N., Legro R. S., Bixler E. O. et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 2. P. 517-520.
  116. Vrbikova J., Bicikova M., Tallova J. et al. Homocysteine and steroid levels in metformin treated women with polycystic ovary syndrome // Exp. Clin. Endocrinol. Diabetes. 2002. Vol. 110. P. 74-76.
  117. Wang J. X., Davies M. J., Norman R. J. Polycystic ovarian syndrome and the risk of spontaneous abortion following assisted reproductive technology treatment // Hum. Reprod. 2001. Vol. 16. № 12. P. 2606-2609.
  118. Weerakiet S., Srisombut C., Bunnag P. et al. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome // Int. J. Gynecol. Obstet. 2001. Vol. 75. P. 177-184.
  119. Weiderpass E., Gridley G., Persson I. et al. Risk of endometrial and breast cancer in patients with diabetes mellitus // Int. J. Cancer. 1997. Vol. 71. P. 360-363.
  120. Wenger N. K., Speroff L., Packard B. Cardiovascular health and disease in women // N. Engl. J. Med. 1993. Vol. 329. P. 247.
  121. Weyer C., Funahashi T., Tanaka S. et al. Hypo- adiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia // J. Clin. Endocrinol. Metab. 2001. Vol. 86. № 5. P. 1930-193 5.
  122. Whittemore A. S., Harris R., Itnyre J. The Collaborative Ovarian Cancer Group. Characteristics relating ovarian cancer risk: Collaborative analysis of 12 US case-control studies // Am. J. Epidemiol. 1992. Vol. 136. P. 1184-1203.
  123. Wild R. A. Obesity, lipids, cardiovascular risk, and androgen excess // Am. J. Med. 1995. Vol. 98. P. 27S-32S.
  124. Wild R. A., Alaupovic P., Parker I. J. Lipid and apolipoprotein abnormalities in hirsute women // Am. J. Obstet. Gynecol. 1992. Vol. 166. P. 1191-1197.
  125. Wild R. A., Grubb B. G., Hartz A. et al. Clinical signs of androgen excess as risk factors for coronary artery disease // Fertil. Steril. 1990. Vol. 54. P. 255-259.
  126. Wild S., Pierpoint T., McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study // Clin. Endocrinol. 2000. Vol. 52. P. 595-600.
  127. Wild S., Pierpoint T., Jacobs H., McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study // Hum. Fertil. (Camb). 2000. Vol. 3. №2. P. 101-105.
  128. Worts man J., de Angeles S., Futterweit W. et al. Gestational diabetes and neonatal macrosomia in the polycystic ovary syndrome // J. Reprod. Med. 1991. Vol. 36. P. 659-661.
  129. Wysowski D. K., Comstock G. W, Helsing K. J. et al. Sex hormone levels in relation to development of breast cancer // Am. J. Epidemiol. 1987. Vol. 125. P. 791-799.
  130. Yarali H, Yildirir A., Aybar F. et al. Diastolic dysfunction and increased serum homocysteine concentrations may contribute to increased cardiovascular risk in patients with polycystic ovary syndrome // Fertil. Steril. 2001. Vol. 76. № 3. P. 511-516.
  131. Yildiz B. O.,Haznedaroglu C., Kirazli E., Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state // J. Clin. Endocrinol. Metab. 2002. Vol. 87. № 8. P. 3871-3875.
  132. Yudkin J. S., Kumari M., Humphries S. E., Mohammed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? // Atherosclerosis. 2000. Vol. 148. P. 209-214.
  133. Zimmerman S., Phillips R. A., Wikenfeld C. et al. Polycystic ovary syndrome: lack of hypertension despite insulin resistance // J. Clin. Endocrinol. Metab. 1992. Vol. 75. P. 508-513.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Эко-Вектор, 2003


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.